Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: A meta-analysis and meta-regression of randomised controlled trials

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 18-33

  Shahin, Yousef ^a   Khan, Junaid Alam ^a   Chetter, Ian ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Arterial stiffness; Augmentation index; Pulse wave velocity; Renin angiotensin system; Wave reflections

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LERCANIDIPINE; LISINOPRIL; LOSARTAN; NEBIVOLOL; NITRENDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

ARTERIAL STIFFNESS; ARTERIAL WAVE REFLECTION; AUGMENTATION INDEX; BLOOD PRESSURE; BLOOD VESSEL PARAMETERS; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DRUG DOSE COMPARISON; DRUG EFFECT; EMBASE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; MARFAN SYNDROME; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ELASTICITY; EVIDENCE-BASED MEDICINE; HUMANS; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84857029762     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.005     Document Type: Review

References (99)

1. Safar M.E., Levy B.I., Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003, 107:2864-2869.
2. London G.M., Marchais S.J., Guerin A.P., Pannier B. Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens 2004, 26:689-699.
3. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
4. Blacher J., Guerin A.P., Pannier B., et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99:2434-2439.
5. Arnett D.K., Evans G.W., Riley W.A. Arterial stiffness: a new cardiovascular risk factor?. Am J Epidemiol 1994, 140:669-682.
6. Kawano H., Do Y.S., Kawano Y., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130-1137.
7. Ahimastos A.A., Natoli A.K., Lawler A., Blombery P.A., Kingwell B.A. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005, 45:1194-1199.
8. Yu W.C., Lin Y.P., Lin I.F., Chuang S.Y., Chen C.H. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 2006, 47:478-484.
9. Ahimastos A.A., Aggarwal A., D'Orsa K.M., et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007, 298:1539-1547.
10. Rahman S., Ismail A.A., Ismail S.B., Naing N.N., Abdul Rahman A.R. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 2007, 63:733-741.
11. Mitchell G.F., Dunlap M.E., Warnica W., et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007, 49:1271-1277.
12. Ahimastos A.A., Dart A.M., Lawler A., Blombery P.A., Kingwell B.A. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens 2008, 26:1037-1042.
13. Mahmud A., Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002, 15:321-325.
14. Rajzer M., Klocek M., Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003, 16:439-444.
15. Rehman A., Ismail S.B., Naing L., Roshan T.M., Rahman A.R. Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007, 20:184-189.
16. Ali K., Rajkumar C., Fantin F., Schiff R., Bulpitt C.J. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manage 2009, 5:587-592.
17. London G.M., Pannier B., Guerin A.P., et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994, 90:2786-2796.
18. Mackenzie I.S., McEniery C.M., Dhakam Z., et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009, 54:409-413.
19. Pannier B.M., Guerin A.P., Marchais S.J., London G.M. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001, 28:1074-1077.
20. Breithaupt-Grogler K., Leschinger M., Belz G.G., et al. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther 1996, 10:49-57.
21. Kostka-Jeziorny K., Uruski P., Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press 2011, 20:104-110.
22. Dart A.M., Reid C.M., McGrath B. Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. Am J Hypertens 2001, 14:804-810.
23. Deary A.J., Schumann A.L., Murfet H., et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002, 103:493-499.
24. Tsang T.S., Barnes M.E., Abhayaratna W.P., et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol 2006, 97:916-920.
25. Chen C.H., Ting C.T., Lin S.J., et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995, 25:1034-1041.
26. Neal D.A., Brown M.J., Wilkinson I.B., Byrne C.D., Alexander G.J. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004, 77:748-750.
27. Kaiser T., Heise T., Nosek L., Eckers U., Sawicki P.T. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006, 24:1397-1403.
28. Jiang X.J., O'Rourke M.F., Zhang Y.Q., He X.Y., Liu L.S. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007, 25:1095-1099.
29. Asmar R.G., London G.M., O'Rourke M.E., Safar M.E. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001, 38:922-926.
30. Ferguson J.M., Minas J., Siapantas S., Komesaroff P.A., Sudhir K. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. J Cardiovasc Pharmacol 2008, 51:590-595.
31. Elbourne D.R., Altman D.G., Higgins J.P., et al. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002, 31:140-149.
32. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available from: ; 2008. http://www.cochrane-handbook.org/.
33. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
34. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
35. Benetos A., Vasmant D., Thiery P., Safar M. Effects of ramipril on arterial hemodynamics. J Cardiovasc Pharmacol 1991, 18(Suppl 2):S153-S156.
36. Huang J.-L., Chen Y.-T., Ho H.-Y., et al. Changes of large artery compliance in essential hypertensive subjects after monotherapy with quinapril. Acta Cardiol Sin 1995, 11:106-113.
37. Benetos A., Cambien F., Gautier S., et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996, 28:1081-1084.
38. Asmar R., Topouchian J., Pannier B., Benetos A., Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001, 19:813-818.
39. Lacourciere Y., Beliveau R., Conter H.S., et al. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol 2004, 20:795-799.
40. Asmar R.G., Pannier B., Santoni J.P., et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988, 78:941-950.
41. Benetos A., Asmar R., Vasmant D., Thiery P., Safar M. Long lasting arterial effects of the ACE inhibitor ramipril. J Hum Hypertens 1991, 5:363-368.
42. Manolis A.J., Iraklianou S., Pittaras A., et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens 2005, 18:18-22.
43. Schartl M., Bocksch W.G., Dreysse S., et al. Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens Suppl 1994, 12:S37-S42.
44. Bellido C.A., Iavicoli O.R., Rusak E.J., et al. Continuous improvement of arterial compliance beyond blood pressure decrease after 5 years of antihypertensive treatment. J Clin Hypertens (Greenwich) 2006, 8:555-560.
45. Nagy G., Szijarto I.A., Gaszner B., et al. Effects of mono- and dual blockade of the renin-angiotensin system on markers of cardiovascular status in hypertensive patients with mild and moderate renal failure. Kidney Blood Press Res 2011, 34:150-157.
46. Anan F., Takahashi N., Ooie T., et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005, 61:353-359.
47. Morimoto S., Maki K., Aota Y., Sakuma T., Iwasaka T. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function. Hypertens Res 2008, 31:1603-1610.
48. Kim K.H., Jeong M.H., Cho S.H., et al. Clinical effects of calcium channel blocker and angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris. J Korean Med Sci 2009, 24:223-231.
49. Mimura T., Takenaka T., Kanno Y., et al. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hypertens 2008, 22:38-47.
50. Polonia J., Barbosa L., Silva J.A., Maldonado J. Different influences on central and peripheral pulse pressure, aortic wave reflections and pulse wave velocity of three different types of antihypertensive drugs. Rev Port Cardiol 2003, 22:1485-1492.
51. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
52. Toblli J.E., Bellido C.A., Iavicoli O.R., et al. Pulse wave velocity and urinary albumin excretion in hypertensive patients treated with perindopril. Medicina (B Aires) 2002, 62:544-550.
53. Cameron J.D., McGrath B.P., Dart A.M. Use of radial artery applanation tonometry and a generalized transfer function to determine aortic pressure augmentation in subjects with treated hypertension. J Am Coll Cardiol 1998, 32:1214-1220.
54. Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004, 17:118-123.
55. Kelly R., Daley J., Avolio A., O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989, 14:14-21.
56. Lehmann E.D., Parker J.R., Hopkins K.D., Taylor M.G., Gosling R.G. Validation and reproducibility of pressure-corrected aortic distensibility measurements using pulse-wave-velocity Doppler ultrasound. J Biomed Eng 1993, 15:221-228.
57. Asmar R.G., Topouchian J.A., Benetos A., et al. Non-invasive evaluation of arterial abnormalities in hypertensive patients. J Hypertens Suppl 1997, 15:S99-S107.
58. Asmar R., Benetos A., Topouchian J., et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995, 26:485-490.
59. Davies J.I., Struthers A.D. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003, 21:463-472.
60. Yasmin, Brown M.J. Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. QJM 1999, 92:595-600.
61. Wilkinson I.B., MacCallum H., Hupperetz P.C., et al. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol 2001, 530:541-550.
62. Wilkinson I.B., Mohammad N.H., Tyrrell S., et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002, 15:24-30.
63. Albaladejo P., Asmar R., Safar M., Benetos A. Association between 24-hour ambulatory heart rate and arterial stiffness. J Hum Hypertens 2000, 14:137-141.
64. Lantelme P., Khettab F., Custaud M.A., et al. Spontaneous baroreflex sensitivity: toward an ideal index of cardiovascular risk in hypertension?. J Hypertens 2002, 20:935-944.
65. Sa Cunha R., Pannier B., Benetos A., et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997, 15:1423-1430.
66. Vaitkevicius P.V., Fleg J.L., Engel J.H., et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993, 88:1456-1462.
67. Ong K.T., Delerme S., Pannier B., et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens 2011, 29:1034-1042.
68. Watanabe T., Barker T.A., Berk B.C. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005, 45:163-169.
69. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990, 137:7-12.
70. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991, 68:450-456.
71. Itoh H., Mukoyama M., Pratt R.E., Gibbons G.H., Dzau V.J. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993, 91:2268-2274.
72. Dostal D.E., Booz G.W., Baker K.M. Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem 1996, 157:15-21.
73. Huckle W.R., Earp H.S. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res 1994, 5:177-194.
74. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006, 98:887-896.
75. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
76. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
77. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
78. Barrow S.E., Dollery C.T., Heavey D.J., et al. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol 1986, 87:243-247.
79. O'Kane K.P., Webb D.J., Collier J.G., Vallance P.J. Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 1994, 38:311-315.
80. Mombouli J.V., Illiano S., Nagao T., Scott-Burden T., Vanhoutte P.M. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992, 71:137-144.
81. Linz W., Wohlfart P., Scholkens B.A., Malinski T., Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res 1999, 43:549-561.
82. Brown N.J., Gainer J.V., Murphey L.J., Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000, 102:2190-2196.
83. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994, 87:567-574.
84. Dingemans K.P., Teeling P., Lagendijk J.H., Becker A.E. Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 2000, 258:1-14.
85. Weber K.T., Sun Y., Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994, 23:869-877.
86. Intengan H.D., Thibault G., Li J.S., Schiffrin E.L. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999, 100:2267-2275.
87. Keeley F.W., Elmoselhi A., Leenen F.H. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol 1992, 262:H1013-H1021.
88. Michel J.B., Heudes D., Michel O., et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol 1994, 267:R124-R135.
89. Wojakowski W., Gminski J., Siemianowicz K., Goss M., Machalski M. The influence of angiotensin-converting enzyme inhibitors on the aorta elastin metabolism in diet-induced hypercholesterolaemia in rabbits. J Renin Angiotensin Aldosterone Syst 2001, 2:37-42.
90. Ben Driss A., Himbert C., Poitevin P., et al. Enalapril improves arterial elastic properties in rats with myocardial infarction. J Cardiovasc Pharmacol 1999, 34:102-107.
91. Levy B.I., Michel J.B., Salzmann J.L., et al. Long-term effects of angiotensin-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats. Am J Cardiol 1993, 71:8E-16E.
92. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011, 278:28-45.
93. Rizzoni D., Rossi G.P., Porteri E., et al. Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP. J Hypertens 2004, 22:759-766.
94. McLennan S.V., Kelly D.J., Cox A.J., et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002, 45:268-275.
95. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
96. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
97. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
98. Benetos A., Gautier S., Ricard S., et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996, 94:698-703.
99. Mallareddy M., Parikh C.R., Peixoto A.J. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2006, 8:398-403.